Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the Phase 3 studies BE MOBILE 1 and BE MOBILE 2
SWISS MEDICAL WEEKLY（2023）
Key words
Clinical trial, Randomised trial, Spondyloarthritis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined